Excellent ADC review in lung and breast cancer to keep you up to date!
An excellent and very timely review published a week and a half ago on where we are now with ADCs in lung and breast cancer and what key points we should be considering. Summary below
- The role of antibody-drug conjugates (ADCs) in cancer is evolving rapidly, with 14 ADCs approved and >100 in development
- As the number of available ADCs increases, biomarkers are required to optimise treatment algorithms and patient selection
- Combination therapy of ADCs should be scientifically driven and studied in biomarker-driven trials of enriched populations
- Efforts to optimise ADC treatment duration, sequencing and the potential for ADC rechallenge are essential
- In clinical trials, biopsy sample collection and translational research are critical to improve our understanding of ADCs
- Effective collaborations are required to accelerate progress, which will ultimately help improve patient outcomes
READ THE ARTICLE – https://www.annalsofoncology.org/article/S0923-7534(24)00108-X/abstract